Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Vaccine

COVID-19 vaccine

Brand names: Comirnaty, Spikevax, Nuvaxovid

COVID-19 vaccines are immunising agents used to prevent severe disease from SARS-CoV-2 infection, available in several platforms including mRNA and adenoviral-vector formulations.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

They present the SARS-CoV-2 spike antigen (or instructions to produce it) to the immune system, eliciting neutralising antibody and T-cell responses that provide protection on subsequent exposure.

Prescribing in practice

  • Anaphylaxis is rare but recognised, so vaccinate where resuscitation facilities are available and observe individuals with a relevant allergy history after administration.
  • The MHRA has identified very rare thrombosis with thrombocytopenia after adenoviral-vector vaccines and rare myocarditis/pericarditis after mRNA vaccines; advise on warning symptoms.
  • Eligibility, product choice and timing follow current national immunisation programme advice.

Monitoring

Observe for immediate hypersensitivity after administration and advise reporting of delayed symptoms such as persistent severe headache or chest pain.

Counselling the patient

  • Mild arm soreness, tiredness, headache or low-grade fever for a day or two is common and expected.
  • Seek urgent care for severe or persistent headache, breathlessness, chest pain or new severe swelling after vaccination.
  • Attend for further doses as advised by the national programme.

Evidence & guidelines

Recommendations follow UKHSA/JCVI immunisation guidance and MHRA safety surveillance.

Reference: UK Green Book; Confirm identity and dosing against the manufacturer SPC (eMC) and NICE. Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways